Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.920
-0.021 (-2.25%)
Nov 21, 2024, 4:00 PM EST - Market closed
Xilio Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 61.26 | 44.7 | 120.39 | 198.05 | 19.24 | 48.85 |
Cash & Short-Term Investments | 61.26 | 44.7 | 120.39 | 198.05 | 19.24 | 48.85 |
Cash Growth | 2.49% | -62.87% | -39.22% | 929.49% | -60.61% | - |
Prepaid Expenses | 2.05 | 3.42 | 4.11 | 4.46 | 1.35 | 1.25 |
Other Current Assets | - | - | - | - | - | 1.01 |
Total Current Assets | 63.31 | 48.13 | 124.5 | 202.52 | 20.59 | 51.1 |
Property, Plant & Equipment | 9.57 | 11.2 | 13.06 | 13.9 | 14.06 | 9.87 |
Other Long-Term Assets | 1.78 | 1.6 | 1.61 | 1.64 | 1.66 | 1.75 |
Total Assets | 74.66 | 60.93 | 139.17 | 218.06 | 36.32 | 62.72 |
Accounts Payable | 0.97 | 1.05 | 3.13 | 3.14 | 5.44 | 2.52 |
Accrued Expenses | 9.79 | 10.5 | 10.33 | 8.75 | 13.73 | 2.69 |
Current Portion of Long-Term Debt | - | 3.32 | 6.67 | - | 2.33 | - |
Current Portion of Leases | 1.15 | 1.1 | 1 | 0.88 | 0.65 | - |
Total Current Liabilities | 38.02 | 15.96 | 21.12 | 12.78 | 22.16 | 5.21 |
Long-Term Debt | - | - | 3.17 | 9.63 | 7.81 | 9.97 |
Long-Term Leases | 7.26 | 8.14 | 9.23 | 10.23 | 11.1 | 9.02 |
Other Long-Term Liabilities | - | - | - | - | 0.54 | - |
Total Liabilities | 53.68 | 24.1 | 33.52 | 32.63 | 41.6 | 24.2 |
Common Stock | 0 | 0 | 0 | 0 | - | - |
Additional Paid-In Capital | 391.63 | 362.34 | 354.75 | 346.31 | 1.8 | 0.34 |
Retained Earnings | -370.66 | -325.51 | -249.11 | -160.89 | -85.09 | -29.87 |
Total Common Equity | 20.97 | 36.83 | 105.65 | 185.43 | -83.29 | -29.52 |
Shareholders' Equity | 20.97 | 36.83 | 105.65 | 185.43 | -5.29 | 38.53 |
Total Liabilities & Equity | 74.66 | 60.93 | 139.17 | 218.06 | 36.32 | 62.72 |
Total Debt | 8.42 | 12.55 | 20.07 | 20.74 | 21.89 | 18.99 |
Net Cash (Debt) | 52.84 | 32.15 | 100.32 | 177.32 | -2.65 | 29.86 |
Net Cash Growth | 16.61% | -67.95% | -43.42% | - | - | - |
Net Cash Per Share | 1.20 | 1.17 | 3.66 | 31.63 | -5.06 | 72.95 |
Filing Date Shares Outstanding | 43.96 | 34.47 | 27.43 | 27.36 | 0.81 | 0.41 |
Total Common Shares Outstanding | 43.96 | 27.61 | 27.43 | 27.36 | 0.81 | 0.41 |
Working Capital | 25.29 | 32.17 | 103.38 | 189.74 | -1.57 | 45.9 |
Book Value Per Share | 0.48 | 1.33 | 3.85 | 6.78 | -103.39 | -72.13 |
Tangible Book Value | 20.97 | 36.83 | 105.65 | 185.43 | -83.29 | -29.52 |
Tangible Book Value Per Share | 0.48 | 1.33 | 3.85 | 6.78 | -103.39 | -72.13 |
Machinery | 6.78 | 6.68 | 6.45 | 4.67 | 3.64 | 1.44 |
Construction In Progress | - | - | 0.1 | 0.54 | - | 2.2 |
Leasehold Improvements | 5.12 | 5.12 | 5.12 | 5.12 | 5.09 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.